RxDoctor Payments Data

Joseph Dirocco, MD

Colon & Rectal Surgery · Towson, MDNPI 1326201328

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,933 of the $8,134 with a category attached, or 72.9%. It is spread thinly across 21 manufacturers, the largest accounting for just 17.9%. Reporting peaked in 2019 at $3,144 and has fallen 77.3% since, to $713 in 2025.

$8,134in general payments, 2019–2025

Across 76 payments — averaging $107.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Davol Inc.$1K
  • Intuitive Surgical$1K
  • Covidien LP$1K
  • Johnson & Johnson$796
  • Axonics, Inc.$648
  • Stryker$496
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$1,20115%
  • Food & beverage$5,93373%
  • Education$1,00012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,134 in reported general payments places this provider in the 75th percentile of 29 colon & rectal surgery providers in Maryland.

See all colon & rectal surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$151,586
Medicare patients
296
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MotegrityPrucalopride Succinate12$7,175
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine66$1,894
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,764
Tramadol Hcl32$459
ErythromycinErythromycin Base17$261
Hydrocortisone28$254
Lactulose18$212
Ondansetron OdtOndansetron25$202
Procto-Med HcHydrocortisone11$176
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$144
Metronidazole25$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$47$1,76411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 colon & rectal surgery providers in Maryland.

Other colon & rectal surgery in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →